Evotec SE and Takeda Pharmaceutical Company Ltd. have entered into a multi-RNA target alliance to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Mayo Clinic and Thermo Fisher Scientific are working together to evaluate next-generation sequencing, mass spectrometry and immunology diagnostic tools for multiple applications, including myeloid leukemia and therapeutic drug monitoring panels to deliver access to more precise and personalized insights for patient care.
CYNK-001, a natural killer cell therapy, has received Fast Track designation from FDA for the treatment of adults with recurrent glioblastoma multiforme.
Geneseeq Technology Inc. and Illumina Inc. are working together to develop comprehensive in-vitro diagnostic NGS testing kits (IVD kits) for cancer, using Illumina’s NextSeq 550 Dx sequencing platform.
M2Gen and Merck have entered a new five-year agreement to advance cancer research.
Clayton, Dubilier & Rice funds, the Merck Global Health Innovation Fund (Merck GHI), and McKesson Ventures are investing in M2Gen, an oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders.
FDA has approved Fotivda (tivozanib), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Health Canada has approved Keytruda (pembrolizumab), for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
